The Expanding GLP-1 Drug Pipeline UBT251 is just one of many compounds currently being explored in the growing GLP-1 and incretin drug pipeline
So, this has been of interest to us
Pathological hypertrophy, in contrast, is commonly linked to hypertension, valvular disease, diabetes, obesity, cardiomyopathy, renal disease, or aging and may progress to fibrosis, capillary rarefaction, diastolic dysfunction, systolic failure, arrhythmia, and sudden death ( The adult heart has high ATP demand and normally oxidizes multiple substrates, especially fatty acids, glucose, lactate, ketone bodies, and amino acids
These cardiovascular factors increase the patients overall risk of mortality and morbidity due to potential cardiovascular events such as a myocardial infarction or stroke 1
Its ability to modulate gene expression, promote balanced tissue remodeling, and support regenerative processes makes it particularly interesting for wound healing, skin rejuvenation, and potentially neurodegenerative conditions
This implies that the insertion of the ECD N-terminal helix to the TMD core is a unique feature of compound 2-bound GLP-1R